Novel monoclonal treatments in severe asthma

References

• GINA Report, Global Strategy for Asthma Management and Prevention. Available from: http://www.ginasthma.com.
   Google Scholar
• von Bülow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract 2014;2(6):759–767.
   PubMed Web of Science ®Google Scholar
• Hansen CL, Baelum J, Skadhauge L, Thomsen G, Omland Ø, Thilsing T, Dahl S, Sigsgaard T, Sherson D. Consequences of asthma on job absenteeism and job retention. Scand J Public Health 2012;40(4):377–384.
   PubMed Web of Science ®Google Scholar
• Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998;12(6):1322–1326.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007;62(2):126–133.
   PubMed Web of Science ®Google Scholar
• Guilbert TW, Garris C, Jhingran P, Bonafede M, Tomaszewski KJ, Bonus T, et al. Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life. J Asthma 2011;48(2):126–132.
   PubMed Web of Science ®Google Scholar
• Gold LS, Yeung K, Smith N, Allen-Ramey FC, Nathan RA, Sullivan SD. Asthma control, cost and race: results from a national survey. J Asthma 2013;50(7):783–790.
   PubMed Web of Science ®Google Scholar
• Chung KF. Individual cytokines contributing to asthma pathophysiology: valid targets for asthma therapy? Curr Opin Investig Drugs 2003;4(11):1320–1326.
   PubMedGoogle Scholar
• Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360(10):973–984.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180(5):388–395.
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikuzumab treatment in adults with asthma. N Engl J Med 2011;365(12):1088–1098.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118(11):3546–3556.
   PubMed Web of Science ®Google Scholar
• Coyle AJ, Tsuyuki S. Th2 cells and cytokine networks in allergic inflammation of the lung. Mediators Inflamm 1995;4(4):239–247.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60(3):302–308.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34(4):632–638.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Inter Med 2011;154(9):573–582.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309–316.
   PubMed Web of Science ®Google Scholar
• Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008;102(10):1371–1378.
   PubMed Web of Science ®Google Scholar
• Schumann C, Kropf C, Wibmer T, Rudiger S, Stoiber KM, Thielen A, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2012;6(4):215–227.
   PubMed Web of Science ®Google Scholar
• Vashisht P, Casale T. Omalizumab for treatment of allergic rhinitis. Expert OpinionBiogical Ther 2013;13(6):933–945.
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med 2013;107(8):1141–1151.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma. Chest 2013;143(2):398–405.
   PubMed Web of Science ®Google Scholar
• Barnes N, Menzies-Gow A, Mansur AH, Spencer D, Percival F, Radwan A, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma 2013;50(5):529–536.
   PubMed Web of Science ®Google Scholar
• Takaku Y, Soma T, Nishihara F, Nakagome K, Kobayashi T, Hagiwara K, et al. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma. Int Arch Allergy Immunol 2013;161(Suppl 2):107–117.
   PubMedGoogle Scholar
• Shimizu Y, Dobashi K, Fueki N, Fueki M, Okada T, Tomioka S, et al. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma. J Biol Regul Homeostatic Agents 2011;25(2):177–186.
   PubMed Web of Science ®Google Scholar
• Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Lenczewska D, Bodzenta Lukaszyk A. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy. Int Arch Allergy Immunol 2011;154(1):25–32.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187(8):804–811.
   PubMed Web of Science ®Google Scholar
• Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C, et al. A proof of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to control, nonatopic asthma. Chest 2013;144(2):411–419.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66(5):671–678.
   PubMed Web of Science ®Google Scholar
• Bass P. 2011. Available at: https://www.verywell.com/xolair-for-asthma-all-about-xolair-omalizumab-201163
   Google Scholar
• Yalcin AD, Secil U, Gumuslu S, Strauss LG. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1b and sCD200 in cases of Samter's syndrome: 36 months follow-up. Immunopharmacol Immunotoxicol 2013;35(4):524–527.
   PubMed Web of Science ®Google Scholar
• Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H, Carrigan G. The xolair pregnancy registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol 2015;135(2):407–412.
   Google Scholar
• Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184(10):1125–1132.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360(10):985–993.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005;172(2):149–160.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Singapuri A, Hargadon B, Gupta S, Monteiro W, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol 2014;133(3):921–923.
   PubMed Web of Science ®Google Scholar
• Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010;125(6):1237–1244. e2.
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013;132(5):1086–1096.
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013;41(2):330–338.
   Google Scholar
• De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 2014;133(4):989–996.
   PubMed Web of Science ®Google Scholar
• Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013;132(3):567–574.
   PubMed Web of Science ®Google Scholar
• Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy 2014;44(1):38–46.
   PubMed Web of Science ®Google Scholar
• Hodsman P, Ashman C, Cahn A, De Boever E, Locantore N, Serone A, et al. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br J Clin Pharmacol 2013;75(1):118–128.
   PubMed Web of Science ®Google Scholar
• Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulmon Med 2010;10:3.
   PubMed Web of Science ®Google Scholar
• Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003;300(5625):1527–1528.
   PubMed Web of Science ®Google Scholar
• Otulana BA Wenzel SE, Ind PW, Bowden A, Puthukkeril A, Tomkinson A, et al. A Phase 2b study of inhaled pitrakinra, An IL-4/IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma. Am J Respir Crit Care Med 183;2011:A6179
   Web of Science ®Google Scholar
• Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE, et al. IL-4 eceptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol 2012;130(2):516–522.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007 20;370(9596):1422–1431.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368(26):2455–2466.
   PubMed Web of Science ®Google Scholar
• Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulmon Med 2011;11:14.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47(1):81–87.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Parker JM, Sari S, White B, Molfino N, et al. A randomized, double-blind, placebo controlled multicenter study to evaluate the efficacy of a humanized interleukin-9 monoclonal antibody (MEDI-528) on the late asthmatic response in adults with atopic asthma. Am J Respir Crit Care Med 179;2009:A3639.
   Web of Science ®Google Scholar
• Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 antibody in adults with uncontrolled asthma. Respir Res 2013;14:93.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179(7):549–558.
   PubMed Web of Science ®Google Scholar
• Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008;178(10):1002–1008.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014;370(22):2102–2110.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C, et al. OX40L blockade and allergen-inducedairway responses in subjects with mild asthma. Clin Exp Allergy 2014;44(1):29–37.
   PubMed Web of Science ®Google Scholar
• Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C, Devouassoux G, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe,difficult-to-control, nonatopic asthma. Chest 2013;144(2):411–419.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Levels: a Randomized Phase 3 Study. Chest 2016. pii: S0012-3692(16)47551-3.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3(5):355–366.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014;2(11):879–890.
   PubMed Web of Science ®Google Scholar
• Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med 2015;33(1):14–20.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015;3(9):692–701.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, Walter EH, Nair P. Omalizumab for asthma in adults children. Cochrane Database Syst Rev 2014;13;(1):CD003559.
   Google Scholar
• Kouro T, Takatsu K. IL-5 and eosinophils mediated inflammation: from discovery to therapy. Int Immunol 2009;21:1303–1309.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–1197.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2016;338:2128–2141.
   Google Scholar
• Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388(10039):31–44.
   PubMed Web of Science ®Google Scholar
• Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep 2013;13(5):415–420.
   PubMed Web of Science ®Google Scholar
• Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 1997;99:1492–1499.
   PubMed Web of Science ®Google Scholar
• Dabbagh K, Takeyama K, Lee HM, Ueki IF, Lausier JA, Nadel JA. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immunol 1999;162:6233–6237.
   PubMed Web of Science ®Google Scholar
• Seder RA, Paul WE, Davis MM, Fazekas de St Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992;176:1091–1098.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43(2):343–373.
   PubMed Web of Science ®Google Scholar
• Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012;129(4):983–989.
   PubMed Web of Science ®Google Scholar